

# Carlisle

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	5.5	nc	(nc-nc)	Male	4	3.9	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	7	2.6	267.2	(107.1-550.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	3	1.0	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	25	20.7	121.0	(78.3-178.6)	Female	5	2.2	229.6	(74.0-535.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	9	6.8	132.9	(60.6-252.2)	Female	0	1.8	nc	(nc-nc)
Female	5	4.9	101.6	(32.7-237.1)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	0	1.7	nc	(nc-nc)	Male	34	25.4	133.7	(92.6-186.8)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	3.4	nc	(nc-nc)	Female	2	4.9	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	0	2.0	nc	(nc-nc)	Male	4	11.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	6	8.5	70.7	(25.8-153.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Carver

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	20	12.8	155.8	(95.1-240.6)	Male	11	8.5	129.9	(64.8-232.5)
Female	7	4.7	148.9	(59.6-306.7)	Female	10	6.8	147.2	(70.5-270.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.5	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	4	2.1	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	11	7.4	147.8	(73.7-264.5)
Female	54	49.9	108.2	(81.3-141.2)	Female	11	6.2	176.1	(87.8-315.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.8	nc	(nc-nc)	Male	5	5.3	94.8	(30.5-221.2)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	12	14.9	80.3	(41.5-140.3)	Female	7	4.6	153.7	(61.6-316.6)
Female	15	15.2	98.5	(55.1-162.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	6	4.2	143.7	(52.5-312.7)
Male	4	3.4	nc	(nc-nc)	Female	7	4.6	151.5	(60.7-312.2)
Female	0	1.0	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	62	47.1	131.6	(100.9-168.7)
Male	2	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	0.9	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Testis</u></b>				
Male	10	6.9	145.4	(69.6-267.5)	Male	5	1.7	299.7	(96.6-699.5)
Female	7	4.1	169.1	(67.7-348.4)	<b><u>Thyroid</u></b>				
<b><u>Larynx</u></b>					Male	2	2.9	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	Female	9	8.9	100.9	(46.0-191.5)
Female	0	0.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
<b><u>Leukemia</u></b>					Female	13	11.5	113.3	(60.2-193.7)
Male	7	4.8	146.8	(58.8-302.5)	<b><u>All Sites / Types</u></b>				
Female	6	3.7	164.3	(60.0-357.5)	Male	213	171.3	124.3	(108.2-142.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Female	208	172.8	120.4	(104.6-137.9)
Male	4	3.9	nc	(nc-nc)					
Female	2	1.4	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	24	23.5	102.0	(65.4-151.8)					
Female	34	25.2	135.2	(93.6-188.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Charlemont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	1.4	nc	(nc-nc)	Male	3	1.0	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	10	5.8	173.8	(83.2-319.6)	Female	0	0.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	4	1.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	0	0.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male				
Male	0	0.1	nc	(nc-nc)	Female	3	6.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	2	0.8	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male				
Male	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	0	0.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Female				
Male	0	0.5	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	1	2.7	nc	(nc-nc)	Female	18	20.5	87.8	(52.0-138.7)
Female	3	2.7	nc	(nc-nc)	Male	19	19.4	97.8	(58.8-152.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Charlton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	11.7	111.4	(59.3-190.5)	Male	6	8.2	72.9	(26.6-158.7)
Female	5	3.8	130.4	(42.0-304.4)	Female	3	6.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.5	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	Female	4	1.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	7	7.3	95.5	(38.3-196.8)
Female	57	45.7	124.9	(94.6-161.8)	Female	4	5.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	1.9	nc	(nc-nc)	Male	4	5.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	14	14.5	96.4	(52.7-161.7)	Female	6	4.1	146.0	(53.3-317.7)
Female	10	13.2	75.6	(36.2-139.0)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	2	3.9	nc	(nc-nc)
Male	1	3.3	nc	(nc-nc)	Female	4	3.8	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	33	48.5	68.1	(46.8-95.6)
Male	1	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	0.9	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	1.6	nc	(nc-nc)
Male	3	7.0	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	5	3.5	142.3	(45.9-332.1)	Male	2	1.7	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	1.9	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	11	9.5	115.6	(57.6-206.9)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	4	4.7	nc	(nc-nc)	Female	15	10.0	150.5	(84.2-248.2)
Female	2	3.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	138	168.5	81.9	(68.8-96.7)
Male	3	3.9	nc	(nc-nc)	Female	183	152.5	120.0	(103.3-138.7)
Female	2	1.1	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	19	21.5	88.3	(53.2-138.0)					
Female	26	19.4	134.3	(87.7-196.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chatham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	20	15.9	126.0	(76.9-194.6)	Male	20	9.1	219.1	(133.8-338.4)
Female	9	5.7	157.8	(72.0-299.6)	Female	12	6.0	199.4	(102.9-348.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.2	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	8	7.9	101.3	(43.6-199.5)
Female	74	45.6	162.4	(127.5-203.9)	Female	7	6.8	103.2	(41.3-212.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	1.3	nc	(nc-nc)	Male	8	5.4	148.3	(63.8-292.2)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	18	17.1	105.4	(62.4-166.6)	Female	5	4.4	112.8	(36.3-263.2)
Female	13	18.2	71.5	(38.0-122.3)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	5	5.0	99.4	(32.0-231.9)
Male	5	4.0	123.9	(39.9-289.1)	Female	4	5.7	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	64	60.6	105.7	(81.4-135.0)
Male	1	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	2	2.2	nc	(nc-nc)
Male	7	7.4	94.2	(37.8-194.2)	<b><u>Testis</u></b>				
Female	8	4.2	192.1	(82.7-378.6)	Male	1	0.7	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	2.3	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	5.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	6	5.1	116.8	(42.7-254.3)	Female	8	10.7	74.9	(32.3-147.6)
Female	2	3.8	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	212	201.1	105.4	(91.7-120.6)
Male	1	4.2	nc	(nc-nc)	Female	199	174.5	114.0	(98.7-131.0)
Female	1	1.5	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	22	29.4	74.9	(46.9-113.4)					
Female	25	28.4	88.1	(57.0-130.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chelmsford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	31	37.2	83.3	(56.6-118.2)	Male	30	24.9	120.3	(81.2-171.8)
Female	24	14.2	168.5	(107.9-250.7)	Female	22	20.6	107.0	(67.0-162.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	7.3	136.9	(65.6-251.9)	Male	11	6.6	166.0	(82.8-297.1)
Female	5	6.4	78.1	(25.2-182.3)	Female	8	5.5	145.9	(62.8-287.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	19	21.9	86.9	(52.3-135.7)
Female	194	151.8	127.8	(110.4-147.1)	Female	21	18.9	111.2	(68.8-169.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	5.6	88.9	(28.6-207.4)	Male	23	16.0	143.8	(91.1-215.7)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	52	44.3	117.3	(87.6-153.9)	Female	10	13.9	72.0	(34.5-132.4)
Female	44	46.5	94.6	(68.7-127.0)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	9	10.1	89.0	(40.6-169.0)	Male	11	12.2	90.0	(44.9-161.1)
Female	7	3.0	234.5	(94.0-483.2)	Female	12	14.0	85.6	(44.2-149.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Stomach</u></b>				
Male	3	2.9	nc	(nc-nc)	Male	8	8.8	91.0	(39.2-179.3)
Female	2	2.5	nc	(nc-nc)	Female	5	5.5	90.2	(29.1-210.4)
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Testis</u></b>				
Male	17	20.7	82.1	(47.8-131.5)	Male	4	4.5	nc	(nc-nc)
Female	11	12.4	88.5	(44.1-158.4)	<b><u>Thyroid</u></b>				
<b><u>Larynx</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	5.9	nc	(nc-nc)	Female	40	35.0	114.3	(81.6-155.6)
Female	4	1.9	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	19	14.0	135.6	(81.6-211.8)	Male	524	513.5	102.0	(93.5-111.2)
Female	18	11.0	163.5	(96.9-258.4)	Female	589	523.2	112.6	(103.7-122.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>									
Male	14	11.8	118.5	(64.8-198.9)					
Female	4	4.1	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	70	69.0	101.5	(79.1-128.2)					
Female	69	74.6	92.5	(71.9-117.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chelsea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	19	28.1	67.6	(40.7-105.6)	Male	6	19.3	31.1	(11.4-67.7)
Female	7	9.4	74.8	(30.0-154.0)	Female	4	15.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	6.3	143.1	(65.3-271.6)	Male	2	4.9	nc	(nc-nc)
Female	0	5.1	nc	(nc-nc)	Female	7	3.6	196.7	(78.8-405.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	17	17.0	99.9	(58.1-159.9)
Female	77	100.6	76.5	(60.4-95.6)	Female	12	12.9	93.2	(48.1-162.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	8	4.6	175.6	(75.6-346.1)	Male	9	11.6	77.6	(35.4-147.4)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	29	33.1	87.7	(58.7-126.0)	Female	3	9.4	nc	(nc-nc)
Female	37	31.4	117.9	(83.0-162.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	5	7.3	68.5	(22.1-159.9)	Male	65	103.3	62.9	(48.6-80.2)
Female	2	1.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	1	3.1	nc	(nc-nc)	Male	2	5.8	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	19	15.3	124.2	(74.7-194.0)	Female	16	22.1	72.3	(41.3-117.4)
Female	14	8.3	168.8	(92.2-283.2)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	5	4.2	118.7	(38.3-277.0)	Male	13	11.4	113.6	(60.4-194.2)
Female	1	1.2	nc	(nc-nc)	Female	4	8.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	11	8.5	129.6	(64.6-231.9)	Male	79	50.6	156.3	(123.7-194.8)
Female	4	2.7	nc	(nc-nc)	Female	55	47.5	115.9	(87.3-150.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Cheshire

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	4.8	166.1	(71.5-327.2)	Male	8	3.1	261.6	(112.6-515.5)
Female	1	1.3	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	11	14.6	75.5	(37.6-135.1)	Female	1	1.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	5	5.3	94.1	(30.3-219.6)	Female	4	1.3	nc	(nc-nc)
Female	2	4.3	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	0	1.5	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	27	17.8	152.1	(100.2-221.3)
Male	1	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.5	nc	(nc-nc)
Male	4	2.5	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	2	1.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	1.7	nc	(nc-nc)	Female	7	3.4	205.3	(82.2-423.0)
Female	0	1.0	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	82	63.0	130.2	(103.5-161.6)
Male	1	1.5	nc	(nc-nc)	Female	38	49.4	76.9	(54.4-105.6)
Female	0	0.4	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	12	8.8	136.7	(70.5-238.7)					
Female	2	7.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	7	5.4	129.3	(51.8-266.4)	Female	0	0.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	1	2.0	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	1	0.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male				
Male	0	0.1	nc	(nc-nc)	Female	6	7.8	77.1	(28.1-167.8)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	0	1.0	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male				
Male	1	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	0	0.6	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Female				
Male	1	0.6	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	2	3.2	nc	(nc-nc)	Female	19	24.3	78.3	(47.1-122.4)
Female	4	2.5	nc	(nc-nc)	Female	17	18.0	94.3	(54.9-150.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chesterfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	4	5.3	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	0	1.7	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	0	0.4	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	6	5.2	116.5	(42.5-253.5)
Male	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	0.5	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	16	18.4	86.7	(49.5-140.8)
Male	0	0.4	nc	(nc-nc)	Female	13	17.2	75.6	(40.2-129.3)
Female	0	0.1	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	4	2.4	nc	(nc-nc)					
Female	1	2.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chicopee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	67	63.0	106.4	(82.5-135.1)	Male	25	40.7	61.4	(39.7-90.6)
Female	12	25.4	47.3	(24.4-82.5)	Female	14	34.4	40.8	(22.3-68.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	12	11.8	101.9	(52.6-178.1)	Male	13	10.8	120.7	(64.2-206.4)
Female	14	10.9	129.0	(70.5-216.4)	Female	8	9.6	83.3	(35.9-164.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	2.0	nc	(nc-nc)	Male	34	36.1	94.2	(65.2-131.7)
Female	239	245.2	97.5	(85.5-110.6)	Female	28	32.7	85.6	(56.9-123.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	10	8.8	113.6	(54.4-208.9)	Male	25	25.8	97.0	(62.8-143.2)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	59	73.0	80.8	(61.5-104.2)	Female	19	23.0	82.6	(49.7-129.0)
Female	85	82.6	103.0	(82.2-127.3)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	19	16.7	113.9	(68.5-177.9)	Male	20	20.3	98.4	(60.1-152.0)
Female	2	5.4	nc	(nc-nc)	Female	25	25.1	99.4	(64.3-146.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Stomach</u></b>				
Male	5	5.1	97.6	(31.4-227.7)	Male	21	14.7	143.2	(88.6-218.9)
Female	3	4.5	nc	(nc-nc)	Female	15	10.0	150.4	(84.1-248.1)
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Testis</u></b>				
Male	27	33.3	81.1	(53.5-118.0)	Male	10	7.9	126.2	(60.4-232.0)
Female	27	20.9	129.1	(85.1-187.8)	<b><u>Thyroid</u></b>				
<b><u>Larynx</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	7	9.7	72.3	(29.0-149.0)	Female	54	56.4	95.8	(72.0-125.0)
Female	5	3.1	163.9	(52.8-382.5)	<b><u>All Sites / Types</u></b>				
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	18	23.3	77.2	(45.7-122.0)	Male	797	846.4	94.2	(87.7-100.9)
Female	14	19.2	72.8	(39.8-122.2)	Female	848	882.2	96.1	(89.8-102.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	15	19.1	78.4	(43.8-129.3)	<b><u>All Sites / Types</u></b>				
Female	8	7.1	112.0	(48.2-220.7)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					<b><u>All Sites / Types</u></b>				
Male	155	114.9	134.9	(114.5-157.9)	<b><u>All Sites / Types</u></b>				
Female	161	130.5	123.4	(105.1-144.0)	<b><u>All Sites / Types</u></b>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chilmark

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.9	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	6	4.9	123.2	(45.0-268.2)	Female	0	0.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	6	2.1	288.7	(105.4-628.3)	Female	0	0.5	nc	(nc-nc)
Female	3	1.5	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	0	0.5	nc	(nc-nc)	0	0.6	nc	(nc-nc)	
Female	0	0.1	nc	(nc-nc)	Female				
<b><u>Hodgkin Lymphoma</u></b>					2				
Male	0	0.1	nc	(nc-nc)	0.5				
Female	0	0.1	nc	(nc-nc)	nc				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Prostate</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	13	7.2	180.5	(96.0-308.7)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Larynx</u></b>					Male				
Male	0	0.3	nc	(nc-nc)	0	0.4	nc	(nc-nc)	
Female	0	0.1	nc	(nc-nc)	Female				
<b><u>Leukemia</u></b>					0				
Male	1	0.7	nc	(nc-nc)	0.2				
Female	0	0.3	nc	(nc-nc)	nc				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Testis</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	1	3.5	nc	(nc-nc)	1	0.3	nc	(nc-nc)	
Female	2	2.5	nc	(nc-nc)	Female				
					0				
					0.8				
					nc				
					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
					Female				
					0				
					1.2				
					nc				
					<b><u>All Sites / Types</u></b>				
					Male				
					29				
					24.4				
					118.9				
					(79.6-170.8)				
					Female				
					15				
					16.9				
					89.0				
					(49.8-146.7)				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Clarksburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	2.4	206.8	(66.6-482.6)	Male	0	1.6	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	1	7.8	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	2	2.9	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	5	2.4	212.4	(68.4-495.6)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	2	0.7	nc	(nc-nc)	Male	7	10.2	68.8	(27.6-141.7)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	1.3	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	5	4.5	110.2	(35.5-257.2)
Female	0	0.2	nc	(nc-nc)	Female	3	3.9	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Clinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	12.5	48.2	(17.6-104.9)	Male	7	8.7	80.4	(32.2-165.7)
Female	5	5.5	90.8	(29.3-211.9)	Female	4	8.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.7	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
Female	4	2.5	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	4	7.7	nc	(nc-nc)
Female	58	56.7	102.3	(77.7-132.3)	Female	4	7.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.2	nc	(nc-nc)	Male	6	5.6	107.2	(39.2-233.4)
<b><u>Colon / Rectum</u></b>					Female	3	2.9	nc	(nc-nc)
Male	13	15.1	85.9	(45.7-147.0)	<b><u>Ovary</u></b>				
Female	22	18.2	120.6	(75.5-182.6)	Female	0	5.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	3.4	nc	(nc-nc)	Male	4	4.1	nc	(nc-nc)
Female	4	1.2	nc	(nc-nc)	Female	7	5.5	128.4	(51.4-264.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	36	49.9	72.2	(50.5-99.9)
Female	0	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	3.0	200.2	(73.1-435.8)
Male	6	7.2	83.2	(30.4-181.2)	Female	2	2.2	nc	(nc-nc)
Female	9	4.7	191.8	(87.5-364.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	2.1	nc	(nc-nc)
Male	4	2.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	10.7	93.6	(44.8-172.2)
Male	2	4.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	4.3	nc	(nc-nc)	Female	15	12.8	117.1	(65.5-193.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	4.1	nc	(nc-nc)	Male	148	176.5	83.9	(70.9-98.5)
Female	3	1.6	nc	(nc-nc)	Female	203	199.6	101.7	(88.2-116.7)
<b><u>Lung and Bronchus</u></b>									
Male	28	23.1	121.4	(80.6-175.4)					
Female	34	28.2	120.5	(83.4-168.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Cohasset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	9.1	55.0	(17.7-128.4)	Male	12	5.7	208.9	(107.8-365.0)
Female	3	3.2	nc	(nc-nc)	Female	12	4.5	267.7	(138.2-467.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	1.7	299.9	(96.6-699.8)	Male	3	1.6	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	3	5.2	nc	(nc-nc)
Female	29	33.9	85.6	(57.3-122.9)	Female	2	4.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.2	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	18	10.6	169.2	(100.2-267.4)	Female	5	3.1	161.9	(52.2-377.9)
Female	10	10.7	93.7	(44.9-172.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	2	2.9	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	Female	2	3.2	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	37	32.4	114.0	(80.3-157.2)
Male	3	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	1.3	nc	(nc-nc)
Male	4	4.8	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	7	2.8	252.1	(101.0-519.5)	Male	0	0.8	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	7	5.7	122.5	(49.1-252.5)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	3.4	nc	(nc-nc)	Female	9	7.7	116.5	(53.2-221.1)
Female	2	2.5	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	122	118.8	102.7	(85.3-122.6)
Male	2	2.8	nc	(nc-nc)	Female	125	117.0	106.8	(88.9-127.3)
Female	0	0.9	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	10	16.3	61.2	(29.3-112.6)					
Female	14	16.8	83.4	(45.5-139.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Colrain

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	2.3	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	6	7.2	83.8	(30.6-182.3)	Female	0	0.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	3	2.8	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	0	0.8	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	4	9.4	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.2	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.9	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	17	32.2	52.8	(30.7-84.5)
Male	1	0.7	nc	(nc-nc)	Female	24	24.0	100.1	(64.1-149.0)
Female	0	0.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	3	4.3	nc	(nc-nc)					
Female	3	3.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Concord

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	21	22.1	95.2	(58.9-145.5)	Male	32	14.8	216.9	(148.3-306.1)
Female	5	8.6	57.9	(18.6-135.1)	Female	12	11.0	108.7	(56.1-189.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	4.3	nc	(nc-nc)	Male	1	3.9	nc	(nc-nc)
Female	5	3.5	142.9	(46.0-333.4)	Female	4	3.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	11	13.0	84.8	(42.3-151.8)
Female	108	83.8	128.9	(105.7-155.6)	Female	10	11.0	91.2	(43.7-167.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.8	nc	(nc-nc)	Male	8	9.6	83.0	(35.7-163.5)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	25	26.3	95.1	(61.5-140.4)	Female	7	7.8	89.7	(35.9-184.8)
Female	32	28.4	112.7	(77.1-159.1)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	9	7.2	124.4	(56.8-236.2)
Male	3	6.0	nc	(nc-nc)	Female	7	8.6	81.7	(32.7-168.3)
Female	0	1.8	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	109	86.2	126.4	(103.8-152.5)
Male	2	1.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	1.2	nc	(nc-nc)	Male	1	5.2	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	3.4	nc	(nc-nc)
Male	16	12.2	131.2	(75.0-213.1)	<b><u>Testis</u></b>				
Female	5	7.0	71.6	(23.1-167.1)	Male	2	2.7	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	3.5	nc	(nc-nc)	Male	5	5.1	98.3	(31.7-229.5)
Female	0	1.0	nc	(nc-nc)	Female	12	13.1	91.6	(47.3-160.0)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	9	8.2	110.1	(50.2-209.0)	Female	23	19.3	119.2	(75.5-178.9)
Female	4	6.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	298	303.1	98.3	(87.5-110.1)
Male	2	7.2	nc	(nc-nc)	Female	292	296.6	98.5	(87.5-110.4)
Female	3	2.4	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	20	40.7	49.2	(30.0-75.9)					
Female	22	43.3	50.8	(31.8-76.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Conway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	11	8.3	132.3	(66.0-236.8)	Female	1	0.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	2	2.4	nc	(nc-nc)	Female	3	0.7	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	1	0.6	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	13	7.7	169.1	(90.0-289.2)
Male	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	0.2	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.7	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	31	27.5	112.6	(76.5-159.8)
Male	0	0.7	nc	(nc-nc)	Female	25	26.7	93.7	(60.7-138.4)
Female	0	0.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	2	3.5	nc	(nc-nc)					
Female	0	3.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Cummington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.6	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	3	4.0	nc	(nc-nc)	Female	3	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	0	1.8	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	4	1.2	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	0	0.5	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	4	5.6	nc	(nc-nc)
Male	1	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.6	nc	(nc-nc)	Female	4	0.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	11	20.5	53.6	(26.7-96.0)
Male	0	0.5	nc	(nc-nc)	Female	20	13.6	147.0	(89.7-227.0)
Female	0	0.1	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	2	2.9	nc	(nc-nc)					
Female	2	1.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dalton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	8.6	81.8	(32.8-168.6)	Male	9	5.3	169.8	(77.5-322.3)
Female	4	3.3	nc	(nc-nc)	Female	3	4.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.5	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	4	4.8	nc	(nc-nc)
Female	25	32.3	77.4	(50.1-114.3)	Female	4	4.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	1.1	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	15	9.8	152.4	(85.3-251.4)	Female	4	3.0	nc	(nc-nc)
Female	17	10.9	156.4	(91.0-250.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	4	2.2	nc	(nc-nc)	Male	0	2.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	3.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	29	29.8	97.4	(65.2-139.8)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	4	4.3	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	0	2.7	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Testis</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	3	3.1	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	0	2.5	nc	(nc-nc)	Female	2	5.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	2.4	nc	(nc-nc)	Female	10	7.4	135.1	(64.7-248.5)
Female	2	0.9	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	13	15.2	85.8	(45.6-146.7)	Male	103	109.8	93.8	(76.6-113.8)
Female	18	16.9	106.4	(63.0-168.1)	Female	106	115.1	92.1	(75.4-111.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Danvers

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	42	36.4	115.3	(83.1-155.8)	Male	25	22.6	110.8	(71.7-163.6)
Female	14	13.1	107.2	(58.5-179.8)	Female	25	17.4	143.5	(92.9-211.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	6.3	111.7	(44.8-230.2)	Male	5	6.1	81.4	(26.2-190.1)
Female	4	5.5	nc	(nc-nc)	Female	3	4.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	16	20.1	79.6	(45.5-129.2)
Female	124	127.3	97.4	(81.0-116.1)	Female	28	16.7	167.3	(111.2-241.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	4.5	nc	(nc-nc)	Male	8	14.1	56.8	(24.4-111.9)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	33	41.9	78.8	(54.2-110.7)	Female	8	11.9	67.4	(29.0-132.9)
Female	43	42.9	100.2	(72.5-134.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	13	11.6	111.8	(59.5-191.3)
Male	10	9.2	108.4	(51.9-199.4)	Female	21	13.0	162.0	(100.3-247.7)
Female	3	2.7	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	152	129.4	117.5	(99.6-137.7)
Male	1	2.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	6	2.1	284.5	(103.9-619.2)	Male	5	8.4	59.6	(19.2-139.0)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	4	5.2	nc	(nc-nc)
Male	26	18.3	142.4	(93.0-208.7)	<b><u>Testis</u></b>				
Female	10	10.7	93.7	(44.8-172.3)	Male	9	3.7	245.9	(112.2-466.8)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	5.3	nc	(nc-nc)	Male	10	7.2	138.8	(66.4-255.2)
Female	2	1.6	nc	(nc-nc)	Female	16	21.5	74.5	(42.5-121.0)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	15	13.2	113.8	(63.6-187.7)	Female	41	29.0	141.6	(101.6-192.1)
Female	14	9.8	142.7	(78.0-239.5)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	503	469.3	107.2	(98.0-117.0)
Male	10	10.5	95.3	(45.6-175.3)	Female	492	453.3	108.5	(99.2-118.6)
Female	8	3.7	218.4	(94.1-430.4)					
<b><u>Lung and Bronchus</u></b>									
Male	78	64.4	121.1	(95.7-151.2)					
Female	67	66.0	101.4	(78.6-128.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dartmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	46	42.8	107.6	(78.7-143.5)	Male	15	27.0	55.5	(31.0-91.5)
Female	22	14.0	156.6	(98.1-237.2)	Female	17	19.3	88.3	(51.4-141.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	7.6	79.4	(29.0-172.8)	Male	4	7.2	nc	(nc-nc)
Female	5	6.0	83.0	(26.7-193.7)	Female	6	5.3	112.7	(41.1-245.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.3	nc	(nc-nc)	Male	18	23.9	75.4	(44.7-119.1)
Female	115	138.4	83.1	(68.6-99.8)	Female	19	18.2	104.6	(62.9-163.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	4.9	nc	(nc-nc)	Male	10	16.9	59.2	(28.3-108.9)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	48	49.2	97.5	(71.9-129.2)	Female	14	13.0	108.0	(59.0-181.2)
Female	44	46.0	95.6	(69.5-128.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	14	13.8	101.7	(55.6-170.7)
Male	12	11.0	109.1	(56.3-190.6)	Female	8	13.9	57.5	(24.8-113.3)
Female	2	2.9	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	200	156.0	128.2	(111.0-147.3)
Male	4	3.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	2.6	nc	(nc-nc)	Male	16	9.8	162.8	(93.0-264.5)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	5.6	nc	(nc-nc)
Male	31	21.7	143.0	(97.1-203.0)	<b><u>Testis</u></b>				
Female	12	11.6	103.4	(53.4-180.6)	Male	3	5.1	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	4	6.3	nc	(nc-nc)	Male	12	8.8	135.7	(70.1-237.1)
Female	1	1.7	nc	(nc-nc)	Female	21	24.0	87.6	(54.2-133.9)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	18	15.6	115.5	(68.4-182.5)	Female	34	31.7	107.2	(74.2-149.8)
Female	10	10.6	94.1	(45.1-173.1)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	588	559.7	105.1	(96.7-113.9)
Male	5	12.5	40.1	(12.9-93.5)	Female	441	492.6	89.5	(81.4-98.3)
Female	3	4.0	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	80	76.4	104.7	(83.0-130.4)					
Female	50	71.6	69.8	(51.8-92.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dedham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	34	31.5	107.9	(74.7-150.8)	Male	21	19.6	107.2	(66.3-163.8)
Female	12	11.8	101.5	(52.4-177.3)	Female	21	15.6	134.2	(83.0-205.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	5.5	108.1	(39.5-235.4)	Male	5	5.3	94.1	(30.3-219.5)
Female	5	4.9	101.7	(32.8-237.4)	Female	2	4.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	0.9	nc	(nc-nc)	Male	17	17.6	96.7	(56.3-154.9)
Female	108	114.0	94.7	(77.7-114.4)	Female	13	15.1	86.0	(45.8-147.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	4.0	148.6	(54.3-323.4)	Male	7	11.9	58.8	(23.6-121.2)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	30	35.9	83.7	(56.4-119.4)	Female	11	10.6	103.3	(51.5-184.9)
Female	34	38.7	87.8	(60.8-122.6)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	9	7.9	114.3	(52.1-216.9)	Male	88	109.9	<b>80.1</b>	<b>(64.2-98.7)</b>
Female	3	2.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	2	2.3	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	6	15.8	<b>38.1</b>	<b>(13.9-82.9)</b>	Female	19	26.0	73.1	(44.0-114.2)
Female	15	9.6	155.6	(87.0-256.7)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	1	4.6	nc	(nc-nc)	Male	11	11.4	96.5	(48.1-172.7)
Female	1	1.4	nc	(nc-nc)	Female	9	8.9	101.3	(46.2-192.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	10	9.0	110.8	(53.1-203.9)	Male	54	56.0	96.4	(72.4-125.8)
Female	3	3.3	nc	(nc-nc)	Female	70	59.9	116.8	(91.0-147.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Deerfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	5.0	nc	(nc-nc)	Male	7	3.6	196.5	(78.7-404.9)
Female	4	2.1	nc	(nc-nc)	Female	3	3.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	23	22.9	100.2	(63.5-150.4)	Female	4	2.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	5	6.1	81.4	(26.2-190.0)	Female	2	2.1	nc	(nc-nc)
Female	1	6.7	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	0	1.7	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	30	22.8	131.7	(88.8-188.0)
Male	1	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	0.8	nc	(nc-nc)
Male	4	3.0	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	2	1.8	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	3	4.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	2.0	nc	(nc-nc)	Female	6	5.4	110.8	(40.5-241.2)
Female	0	1.6	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	75	74.5	100.7	(79.2-126.3)
Male	1	1.8	nc	(nc-nc)	Female	60	77.8	77.1	(58.9-99.3)
Female	0	0.6	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	5	9.6	52.1	(16.8-121.5)					
Female	1	11.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dennis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	36	32.8	109.9	(77.0-152.1)	Male	38	18.4	206.1	(145.8-282.9)
Female	9	11.1	80.9	(36.9-153.5)	Female	29	12.7	227.8	(152.5-327.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	4.6	130.8	(47.8-284.7)	Male	5	5.3	95.0	(30.6-221.6)
Female	5	4.0	124.2	(40.0-289.9)	Female	3	4.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	15	16.3	92.0	(51.4-151.7)
Female	117	96.8	120.9	(99.9-144.8)	Female	14	13.6	102.6	(56.0-172.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.9	nc	(nc-nc)	Male	20	10.7	187.2	(114.3-289.1)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	41	35.0	117.1	(84.0-158.9)	Female	8	9.2	87.1	(37.5-171.6)
Female	40	35.0	114.2	(81.5-155.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	14	10.2	137.5	(75.1-230.7)
Male	8	7.8	102.1	(43.9-201.1)	Female	9	11.0	81.7	(37.3-155.2)
Female	3	2.4	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	137	110.3	124.2	(104.2-146.8)
Male	2	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	1.3	nc	(nc-nc)	Male	3	7.2	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	4	4.3	nc	(nc-nc)
Male	13	14.6	88.9	(47.3-152.0)	<b><u>Testis</u></b>				
Female	13	8.7	149.8	(79.7-256.2)	Male	1	1.7	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	3	4.5	nc	(nc-nc)	Male	3	4.9	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	14	13.4	104.3	(57.0-175.0)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	11	10.7	102.7	(51.2-183.7)	Female	26	22.9	113.5	(74.1-166.3)
Female	13	7.7	169.5	(90.1-289.8)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	452	395.4	114.3	(104.0-125.3)
Male	8	8.4	95.2	(41.0-187.5)	Female	409	358.7	114.0	(103.2-125.6)
Female	4	3.0	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	51	58.3	87.5	(65.2-115.1)					
Female	59	57.9	102.0	(77.6-131.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dighton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	7.2	124.2	(56.7-235.7)	Male	2	4.9	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)	Female	3	3.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	6	4.3	138.8	(50.7-302.0)
Female	22	27.8	79.1	(49.5-119.7)	Female	1	3.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.1	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	12	8.6	139.8	(72.2-244.2)	Female	0	2.5	nc	(nc-nc)
Female	2	8.3	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	5	2.4	208.8	(67.3-487.3)
Male	1	2.1	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	27	30.2	89.4	(58.9-130.0)
Male	2	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	2	1.0	nc	(nc-nc)
Male	8	4.1	195.6	(84.2-385.4)	<b><u>Testis</u></b>				
Female	5	2.2	223.3	(71.9-521.0)	Male	0	1.0	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	5	1.7	289.6	(93.3-675.9)
Female	1	0.3	nc	(nc-nc)	Female	5	5.3	95.0	(30.6-221.6)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	2.7	nc	(nc-nc)	Female	3	6.3	nc	(nc-nc)
Female	4	2.0	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	100	102.3	97.7	(79.5-118.9)
Male	2	2.4	nc	(nc-nc)	Female	78	94.8	82.3	(65.0-102.7)
Female	1	0.7	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	10	13.4	74.8	(35.8-137.5)					
Female	9	13.1	68.6	(31.3-130.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Douglas

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	4.5	133.5	(48.8-290.6)	Male	4	3.9	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)	Female	7	3.8	184.2	(73.8-379.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.3	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
Female	30	26.5	113.1	(76.3-161.5)	Female	2	2.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.2	nc	(nc-nc)	Male	0	2.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	5	6.4	78.4	(25.3-183.0)	Female	1	2.3	nc	(nc-nc)
Female	3	6.9	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	4	1.6	nc	(nc-nc)
Male	4	1.5	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	19	21.4	88.7	(53.4-138.5)
Male	2	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	0.8	nc	(nc-nc)
Male	5	3.4	148.3	(47.8-346.0)	<b><u>Testis</u></b>				
Female	1	2.0	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	5	6.0	83.7	(27.0-195.4)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	2.1	nc	(nc-nc)	Female	9	5.8	155.5	(71.0-295.3)
Female	2	1.8	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	78	74.8	104.3	(82.5-130.2)
Male	3	1.9	nc	(nc-nc)	Female	90	86.2	104.5	(84.0-128.4)
Female	0	0.6	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	8	8.6	92.8	(39.9-182.8)					
Female	16	10.7	150.1	(85.7-243.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	7.1	nc	(nc-nc)	Male	5	4.5	110.3	(35.5-257.4)
Female	0	1.9	nc	(nc-nc)	Female	5	3.0	165.8	(53.4-386.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	9	4.0	223.1	(101.8-423.5)
Female	26	23.4	111.3	(72.7-163.1)	Female	1	2.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	5	8.2	60.7	(19.6-141.6)	Female	0	2.1	nc	(nc-nc)
Female	5	6.1	82.2	(26.5-191.8)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	3	1.9	nc	(nc-nc)	Male	29	26.5	109.6	(73.4-157.4)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	3.8	nc	(nc-nc)	Female	5	5.4	91.9	(29.6-214.6)
Female	1	1.8	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	2	2.2	nc	(nc-nc)	Male	4	12.9	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	8	10.4	77.2	(33.3-152.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dracut

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	38	30.5	124.5	(88.1-170.8)	Male	9	20.7	43.5	(19.8-82.5)
Female	24	10.1	236.6	(151.6-352.1)	Female	15	16.0	93.9	(52.5-154.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	6.1	147.1	(67.1-279.2)	Male	3	5.4	nc	(nc-nc)
Female	8	5.0	160.6	(69.1-316.4)	Female	4	3.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	20	18.0	110.8	(67.7-171.1)
Female	127	114.9	110.6	(92.2-131.5)	Female	11	13.9	79.2	(39.5-141.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	7	4.6	153.7	(61.6-316.6)	Male	13	13.4	97.2	(51.7-166.3)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	54	36.0	150.2	(112.8-195.9)	Female	14	10.4	135.1	(73.8-226.7)
Female	31	33.2	93.5	(63.5-132.7)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	10	8.4	118.8	(56.9-218.5)	Male	8	10.1	79.4	(34.2-156.4)
Female	2	2.1	nc	(nc-nc)	Female	12	9.9	120.7	(62.3-210.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Stomach</u></b>				
Male	2	2.7	nc	(nc-nc)	Male	5	7.2	69.6	(22.4-162.3)
Female	1	2.2	nc	(nc-nc)	Female	8	3.9	204.7	(88.1-403.4)
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Testis</u></b>				
Male	18	17.1	105.5	(62.5-166.8)	Male	1	4.3	nc	(nc-nc)
Female	10	9.3	107.4	(51.4-197.5)	<b><u>Thyroid</u></b>				
<b><u>Larynx</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	4	4.9	nc	(nc-nc)	Female	19	26.1	72.7	(43.7-113.5)
Female	2	1.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	23	11.6	198.9	(126.0-298.4)	Male	418	424.5	98.5	(89.2-108.4)
Female	14	8.2	170.4	(93.1-286.0)	Female	450	390.5	115.2	(104.8-126.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>									
Male	6	9.8	61.3	(22.4-133.3)					
Female	2	3.0	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	57	56.6	100.7	(76.3-130.5)					
Female	70	54.6	128.1	(99.9-161.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dudley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	10.9	109.8	(56.6-191.7)	Male	2	7.6	nc	(nc-nc)
Female	3	3.8	nc	(nc-nc)	Female	4	5.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.3	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	4	6.7	nc	(nc-nc)
Female	41	41.6	98.5	(70.7-133.6)	Female	3	5.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.6	nc	(nc-nc)	Male	3	4.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	21	13.1	160.3	(99.2-245.1)	Female	7	3.8	184.2	(73.8-379.5)
Female	12	12.5	96.3	(49.7-168.2)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	3	3.6	nc	(nc-nc)
Male	4	3.0	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	31	43.6	71.1	(48.3-100.9)
Male	0	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	1.5	nc	(nc-nc)
Male	3	6.2	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	3	3.4	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	3	1.8	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	10	8.1	123.6	(59.2-227.3)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	5	4.3	116.4	(37.5-271.5)	Female	10	9.4	106.3	(50.9-195.5)
Female	2	3.0	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	136	153.7	88.5	(74.3-104.7)
Male	2	3.5	nc	(nc-nc)	Female	139	142.7	97.4	(81.9-115.0)
Female	1	1.1	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	24	20.2	119.0	(76.3-177.1)					
Female	23	19.7	116.6	(73.9-175.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dunstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.2	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	4	0.8	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	11	11.7	93.7	(46.7-167.6)	Female	1	1.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	5	3.1	163.9	(52.8-382.6)	Female	0	1.0	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	0	0.7	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male				
Male	0	0.2	nc	(nc-nc)	Female	7	10.7	65.6	(26.3-135.3)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	2	1.6	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male				
Male	1	0.4	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	4	1.0	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Female				
Male	0	0.9	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	2	4.3	nc	(nc-nc)	Female	31	35.9	86.4	(58.7-122.6)
Female	2	4.6	nc	(nc-nc)	Female	33	36.7	89.9	(61.9-126.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Duxbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	15	17.0	88.4	(49.4-145.7)	Male	33	11.0	301.0	(207.2-422.7)
Female	2	6.3	nc	(nc-nc)	Female	14	9.0	156.2	(85.3-262.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.1	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	1	2.8	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	10	9.7	103.3	(49.5-190.0)
Female	67	67.6	99.0	(76.8-125.8)	Female	6	8.3	72.4	(26.4-157.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.4	nc	(nc-nc)	Male	5	7.3	68.7	(22.2-160.4)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	16	20.0	80.2	(45.8-130.2)	Female	10	6.2	161.8	(77.4-297.5)
Female	15	20.8	72.1	(40.3-118.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	4	5.6	nc	(nc-nc)
Male	8	4.7	170.8	(73.5-336.5)	Female	3	6.2	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	92	68.6	134.1	(108.1-164.5)
Male	3	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	4	1.0	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	3	2.5	nc	(nc-nc)
Male	14	9.2	152.8	(83.4-256.3)	<b><u>Testis</u></b>				
Female	4	5.4	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	2.7	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	15	11.6	128.9	(72.1-212.7)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	6	6.4	94.3	(34.4-205.2)	Female	11	15.5	70.8	(35.3-126.7)
Female	6	4.9	122.8	(44.9-267.4)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	262	232.5	112.7	(99.5-127.2)
Male	3	5.3	nc	(nc-nc)	Female	214	230.6	92.8	(80.8-106.1)
Female	1	1.8	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	20	31.0	64.6	(39.4-99.7)					
Female	21	32.0	65.6	(40.6-100.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# East Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	14.5	62.0	(28.3-117.7)	Male	9	9.5	94.4	(43.1-179.1)
Female	7	4.7	149.6	(59.9-308.3)	Female	11	7.4	147.7	(73.6-264.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.8	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	8	8.5	93.6	(40.3-184.5)
Female	57	53.8	105.9	(80.2-137.2)	Female	12	6.4	186.3	(96.1-325.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.1	nc	(nc-nc)	Male	6	6.2	97.3	(35.5-211.8)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	18	17.7	101.8	(60.3-160.8)	Female	5	4.9	102.5	(33.0-239.3)
Female	16	15.3	104.3	(59.6-169.3)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	7	4.7	148.6	(59.5-306.1)
Male	2	3.8	nc	(nc-nc)	Female	2	4.6	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	57	53.5	106.5	(80.6-138.0)
Male	4	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	1.0	nc	(nc-nc)	Male	5	3.5	143.9	(46.4-335.8)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	1.8	nc	(nc-nc)
Male	13	7.8	167.1	(88.9-285.7)	<b><u>Testis</u></b>				
Female	3	4.3	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	2.2	nc	(nc-nc)	Male	6	3.3	180.0	(65.7-391.7)
Female	1	0.6	nc	(nc-nc)	Female	14	10.5	133.4	(72.9-223.9)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	5.6	nc	(nc-nc)	Female	18	12.4	145.5	(86.2-230.0)
Female	1	3.8	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	198	195.3	101.4	(87.8-116.5)
Male	5	4.4	112.9	(36.4-263.5)	Female	207	181.7	114.0	(99.0-130.6)
Female	1	1.4	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	29	25.6	113.4	(76.0-162.9)					
Female	30	24.9	120.2	(81.1-171.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# East Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	2.4	210.8	(67.9-491.9)	Male	4	1.6	nc	(nc-nc)
Female	3	0.8	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	7	8.6	81.4	(32.6-167.8)	Female	1	1.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	4	2.8	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	0	0.8	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	9	9.7	92.5	(42.2-175.6)
Male	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.3	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.9	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	33	33.3	99.0	(68.2-139.1)
Male	0	0.7	nc	(nc-nc)	Female	30	29.3	102.5	(69.2-146.4)
Female	0	0.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	1	4.5	nc	(nc-nc)					
Female	3	4.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# East Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	24	19.7	121.6	(77.9-180.9)	Male	18	12.5	143.9	(85.2-227.4)
Female	6	8.3	71.9	(26.3-156.5)	Female	8	10.4	77.0	(33.1-151.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.5	nc	(nc-nc)	Male	0	3.4	nc	(nc-nc)
Female	0	3.3	nc	(nc-nc)	Female	4	3.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	12	11.0	109.1	(56.3-190.7)
Female	68	76.0	89.4	(69.5-113.4)	Female	10	10.4	96.1	(46.0-176.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.6	nc	(nc-nc)	Male	7	7.9	88.3	(35.4-181.9)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	18	22.7	79.5	(47.1-125.6)	Female	5	7.2	69.7	(22.5-162.6)
Female	15	27.6	54.3	(30.4-89.6)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	3	5.2	nc	(nc-nc)	Male	88	74.0	118.9	(95.4-146.5)
Female	1	1.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	10	10.2	97.7	(46.8-179.8)	Female	14	17.0	82.3	(45.0-138.1)
Female	8	6.5	123.7	(53.3-243.8)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	5	3.0	167.7	(54.1-391.5)	Male	12	7.1	168.4	(86.9-294.2)
Female	3	0.9	nc	(nc-nc)	Female	0	6.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	4	5.9	nc	(nc-nc)	Male	27	35.9	75.3	(49.6-109.5)
Female	0	2.3	nc	(nc-nc)	Female	32	40.8	78.5	(53.7-110.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Eastham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	11.7	76.9	(35.1-146.0)	Male	11	6.8	162.4	(81.0-290.6)
Female	5	3.5	141.5	(45.6-330.2)	Female	17	4.2	403.9	(235.1-646.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.8	nc	(nc-nc)
Female	36	32.4	111.2	(77.9-153.9)	Female	4	4.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	7	12.5	55.9	(22.4-115.2)	Female	8	3.0	263.9	(113.6-520.1)
Female	9	11.0	81.9	(37.4-155.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	4	3.7	nc	(nc-nc)
Male	0	3.0	nc	(nc-nc)	Female	4	3.5	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	51	43.3	117.8	(87.7-154.9)
Male	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	1.3	nc	(nc-nc)
Male	8	5.4	146.8	(63.2-289.3)	<b><u>Testis</u></b>				
Female	0	2.9	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	4	4.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	8	3.8	211.4	(91.0-416.5)	Female	10	7.8	128.9	(61.7-237.0)
Female	3	2.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	139	146.9	94.6	(79.5-111.7)
Male	1	3.3	nc	(nc-nc)	Female	133	117.4	113.3	(94.8-134.2)
Female	0	1.0	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	14	21.5	65.1	(35.6-109.2)					
Female	15	18.9	79.4	(44.4-131.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Easthampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	17.5	97.1	(56.5-155.5)	Male	8	11.7	68.2	(29.4-134.4)
Female	7	6.9	102.0	(40.9-210.2)	Female	10	10.0	100.1	(47.9-184.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.4	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	5	3.1	163.6	(52.7-381.8)	Female	1	2.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	6	10.4	57.4	(21.0-125.0)
Female	81	71.2	113.8	(90.4-141.5)	Female	8	9.1	88.4	(38.1-174.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	2.7	nc	(nc-nc)	Male	8	7.7	103.6	(44.6-204.2)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	24	21.2	113.1	(72.4-168.2)	Female	6	6.6	91.1	(33.3-198.3)
Female	26	22.6	114.9	(75.1-168.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	4	5.7	nc	(nc-nc)
Male	4	4.7	nc	(nc-nc)	Female	11	6.8	162.4	(80.9-290.5)
Female	3	1.4	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	80	65.8	121.6	(96.4-151.3)
Male	1	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	1.3	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	2	2.7	nc	(nc-nc)
Male	10	9.6	104.2	(49.9-191.7)	<b><u>Testis</u></b>				
Female	9	5.8	153.9	(70.2-292.1)	Male	2	2.4	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	4	2.7	nc	(nc-nc)	Male	1	4.1	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	15	13.2	113.8	(63.6-187.7)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	6	6.6	90.7	(33.1-197.4)	Female	13	16.3	79.6	(42.3-136.1)
Female	4	5.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	239	238.5	100.2	(87.9-113.8)
Male	2	5.7	nc	(nc-nc)	Female	257	249.0	103.2	(91.0-116.6)
Female	2	2.0	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	32	31.5	101.6	(69.5-143.4)					
Female	28	35.2	79.6	(52.9-115.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Easton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	22	21.0	104.8	(65.6-158.7)	Male	17	14.7	115.7	(67.4-185.3)
Female	5	7.1	70.5	(22.7-164.6)	Female	22	12.0	183.9	(115.2-278.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	4.5	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
Female	8	3.7	214.9	(92.5-423.5)	Female	4	2.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	0.7	nc	(nc-nc)	Male	11	12.9	85.2	(42.5-152.5)
Female	108	85.5	126.4	(103.6-152.6)	Female	15	10.0	150.4	(84.1-248.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.4	nc	(nc-nc)	Male	5	10.0	50.1	(16.2-117.0)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	23	25.6	89.9	(56.9-134.8)	Female	8	7.7	103.6	(44.6-204.1)
Female	28	23.5	119.0	(79.1-172.0)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	5	7.1	70.8	(22.8-165.2)
Male	10	6.1	164.8	(78.9-303.1)	Female	8	6.9	115.5	(49.7-227.6)
Female	2	1.5	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	77	89.3	86.2	(68.0-107.7)
Male	1	2.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	1.8	nc	(nc-nc)	Male	6	5.1	117.9	(43.1-256.6)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	2.8	nc	(nc-nc)
Male	8	12.3	64.8	(27.9-127.7)	<b><u>Testis</u></b>				
Female	12	6.7	178.7	(92.3-312.2)	Male	7	3.2	220.9	(88.5-455.2)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	5	3.5	142.4	(45.9-332.2)	Male	9	5.4	167.9	(76.6-318.7)
Female	0	1.0	nc	(nc-nc)	Female	24	17.3	139.1	(89.1-207.0)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	9	8.3	108.8	(49.6-206.5)	Female	16	19.6	81.8	(46.7-132.8)
Female	8	5.9	134.8	(58.1-265.7)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	288	303.8	94.8	(84.2-106.4)
Male	10	7.1	140.3	(67.2-258.0)	Female	330	284.6	116.0	(103.8-129.2)
Female	2	2.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	34	39.4	86.4	(59.8-120.7)					
Female	29	38.0	76.4	(51.2-109.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Edgartown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	4.9	102.8	(33.1-239.9)	Male	8	3.5	226.9	(97.7-447.1)
Female	3	1.5	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
Female	12	17.3	69.3	(35.8-121.1)	Female	4	2.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	3	6.2	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
Female	5	4.9	102.3	(33.0-238.6)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	0	1.7	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	Female	5	1.5	335.9	(108.2-783.8)
Female	0	0.3	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	25	22.4	111.7	(72.3-164.9)
Male	1	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	0.3	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.6	nc	(nc-nc)
Male	2	3.0	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	1.4	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	2	3.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	1.9	nc	(nc-nc)	Female	7	4.1	171.1	(68.5-352.5)
Female	2	1.2	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	64	73.2	87.5	(67.3-111.7)
Male	0	1.9	nc	(nc-nc)	Female	66	58.5	112.9	(87.3-143.7)
Female	0	0.5	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	7	9.2	76.3	(30.6-157.3)					
Female	11	8.4	131.7	(65.6-235.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Egremont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.9	nc	(nc-nc)	Male	4	1.7	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	6	7.5	79.9	(29.2-174.0)	Female	1	0.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	3	3.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	3	10.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	1.3	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	3	5.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	3.9	nc	(nc-nc)
					Male	20	36.0	55.5	(33.9-85.8)
					Female	16	25.9	61.9	(35.4-100.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Erving

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	6	7.1	84.9	(31.0-184.7)	Female	1	0.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	6	2.2	272.0	(99.3-592.1)	Female	1	0.7	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	2	0.5	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male				
Male	0	0.2	nc	(nc-nc)	Female	7	7.8	90.3	(36.2-186.0)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	0	1.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male				
Male	0	0.3	nc	(nc-nc)	Female	2	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	0	0.7	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Female				
Male	0	0.6	nc	(nc-nc)	Male	4	1.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	4	3.3	nc	(nc-nc)	Female	25	26.1	95.8	(62.0-141.5)
Female	2	3.4	nc	(nc-nc)	Female	24	24.3	98.8	(63.3-147.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Essex

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	3.5	229.6	(98.9-452.4)	Male	2	2.5	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
Female	7	14.5	48.3	(19.3-99.5)	Female	0	1.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	0.5	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	3	4.5	nc	(nc-nc)	Female	3	1.3	nc	(nc-nc)
Female	3	4.2	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	0	1.2	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	15	14.6	102.4	(57.3-169.0)
Male	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	0.5	nc	(nc-nc)
Male	1	2.1	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	1.2	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	0.6	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	4	1.4	nc	(nc-nc)	Female	3	3.3	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	61	50.9	119.7	(91.6-153.8)
Male	0	1.3	nc	(nc-nc)	Female	37	49.1	75.4	(53.1-103.9)
Female	0	0.4	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	10	6.5	153.6	(73.5-282.5)					
Female	2	6.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Everett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	34	33.3	102.2	(70.8-142.9)	Male	20	22.5	88.9	(54.3-137.4)
Female	8	14.5	55.0	(23.7-108.5)	Female	9	21.8	41.2	(18.8-78.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	7.1	84.2	(30.7-183.2)	Male	8	5.6	141.7	(61.0-279.1)
Female	7	6.9	101.9	(40.8-210.0)	Female	3	5.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	22	20.1	109.3	(68.5-165.6)
Female	129	150.9	85.5	(71.4-101.6)	Female	17	19.4	87.8	(51.1-140.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	6.0	82.7	(26.7-193.0)	Male	16	14.0	114.6	(65.5-186.1)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	46	40.3	114.2	(83.6-152.3)	Female	15	14.0	107.5	(60.1-177.3)
Female	48	47.8	100.5	(74.1-133.2)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	15	10.8	139.5	(78.0-230.1)
Male	9	8.5	105.8	(48.3-200.9)	Female	14	14.4	97.5	(53.3-163.6)
Female	1	3.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	101	117.8	85.7	(69.8-104.2)
Male	4	3.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	5	3.1	160.8	(51.8-375.3)	Male	16	7.9	201.7	(115.2-327.5)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	13	5.8	225.8	(120.1-386.2)
Male	22	17.9	123.1	(77.1-186.4)	<b><u>Testis</u></b>				
Female	10	12.6	79.6	(38.1-146.4)	Male	3	6.4	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	5	4.9	102.7	(33.1-239.6)	Male	9	8.2	109.6	(50.0-208.1)
Female	4	1.8	nc	(nc-nc)	Female	25	29.7	84.2	(54.5-124.3)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	7	13.5	51.8	(20.7-106.7)	Female	31	33.9	91.4	(62.1-129.7)
Female	13	11.6	111.6	(59.4-190.9)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	470	447.5	105.0	(95.8-115.0)
Male	14	9.8	142.2	(77.7-238.5)	Female	505	532.3	94.9	(86.8-103.5)
Female	8	4.2	191.5	(82.5-377.3)					
<b><u>Lung and Bronchus</u></b>									
Male	75	58.0	129.3	(101.7-162.1)					
Female	105	75.3	139.4	(114.0-168.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Fairhaven

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	24	21.4	112.0	(71.7-166.6)	Male	9	13.3	67.7	(30.9-128.6)
Female	12	8.9	134.5	(69.4-235.0)	Female	17	11.2	152.0	(88.5-243.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.6	nc	(nc-nc)	Male	9	3.6	250.6	(114.4-475.8)
Female	5	3.5	143.3	(46.2-334.4)	Female	4	3.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	0.7	nc	(nc-nc)	Male	12	11.8	101.8	(52.5-177.8)
Female	87	80.9	107.5	(86.1-132.6)	Female	7	11.1	62.8	(25.2-129.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.8	nc	(nc-nc)	Male	10	8.2	121.3	(58.1-223.1)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	26	24.6	105.8	(69.1-155.0)	Female	7	7.7	91.0	(36.5-187.6)
Female	31	29.5	105.2	(71.5-149.3)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	7	6.8	102.2	(41.0-210.6)
Male	3	5.5	nc	(nc-nc)	Female	11	8.9	123.4	(61.5-220.9)
Female	0	1.9	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	99	77.7	127.3	(103.5-155.0)
Male	2	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	1.3	nc	(nc-nc)	Male	10	4.9	203.3	(97.3-373.8)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	4	3.6	nc	(nc-nc)
Male	10	10.8	92.9	(44.5-170.8)	<b><u>Testis</u></b>				
Female	9	6.9	130.0	(59.3-246.9)	Male	1	2.1	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	6	3.2	189.7	(69.3-412.9)	Male	5	4.2	118.6	(38.2-276.8)
Female	7	1.0	704.4	(282.2-1451.5)	Female	15	13.0	115.1	(64.4-189.9)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	10	7.7	130.0	(62.2-239.1)	Female	11	18.3	60.0	(29.9-107.5)
Female	7	6.5	107.2	(42.9-220.8)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	338	277.9	121.6	(109.0-135.3)
Male	5	6.2	81.2	(26.2-189.6)	Female	333	296.2	112.4	(100.7-125.2)
Female	2	2.4	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	55	38.6	142.5	(107.4-185.5)					
Female	63	43.8	143.9	(110.6-184.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Fall River

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	108	94.9	113.9	(93.4-137.5)	Male	45	61.1	73.6	(53.7-98.5)
Female	44	41.0	107.3	(78.0-144.0)	Female	26	55.2	47.1	(30.8-69.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	18	18.1	99.3	(58.8-157.0)	Male	19	16.2	117.5	(70.7-183.5)
Female	12	17.6	68.2	(35.2-119.1)	Female	13	15.3	84.7	(45.1-144.9)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	2.9	nc	(nc-nc)	Male	47	54.2	86.7	(63.7-115.3)
Female	272	383.3	71.0	(62.8-79.9)	Female	60	52.4	114.5	(87.4-147.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	18	14.2	126.8	(75.1-200.4)	Male	47	37.7	124.7	(91.6-165.8)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	121	109.3	110.7	(91.8-132.2)	Female	33	36.4	90.6	(62.4-127.3)
Female	145	135.0	107.4	(90.6-126.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	31	24.5	126.7	(86.1-179.8)	Male	296	346.1	85.5	(76.1-95.8)
Female	4	8.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	8	8.2	97.2	(41.9-191.5)	Male	13	13.5	96.2	(51.2-164.6)
Female	3	7.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	47	48.9	96.1	(70.6-127.8)	Female	94	86.6	108.5	(87.7-132.8)
Female	33	32.8	100.5	(69.2-141.1)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	26	14.0	185.1	(120.9-271.2)	Male	1333	1254.0	106.3	(100.7-112.2)
Female	8	4.7	170.1	(73.2-335.2)	Female	1325	1402.1	94.5	(89.5-99.7)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	31	35.9	86.4	(58.7-122.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	43	31.5	136.4	(98.7-183.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	27	28.0	96.6	(63.6-140.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	11	11.4	96.9	(48.3-173.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
<b><u>Lung and Bronchus</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	249	169.5	146.9	(129.2-166.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	210	204.4	102.7	(89.3-117.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Falmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	64	59.8	107.0	(82.4-136.7)	Male	30	35.3	85.0	(57.3-121.4)
Female	14	20.2	69.3	(37.8-116.2)	Female	29	24.7	117.6	(78.8-168.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	15	9.0	166.1	(92.9-273.9)	Male	9	9.9	91.0	(41.5-172.8)
Female	9	7.7	116.2	(53.0-220.5)	Female	6	7.6	79.0	(28.9-172.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	1.8	nc	(nc-nc)	Male	30	30.7	97.7	(65.9-139.5)
Female	219	185.5	118.1	(103.0-134.8)	Female	27	25.3	106.8	(70.4-155.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	6.0	83.8	(27.0-195.4)	Male	26	21.5	120.8	(78.9-177.1)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	54	65.7	82.2	(61.7-107.2)	Female	27	17.5	154.6	(101.9-224.9)
Female	53	64.4	82.3	(61.7-107.7)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male 21 19.1 109.7 (67.9-167.7)				
Male	15	15.3	98.3	(55.0-162.1)	Female 19 20.0 95.1 (57.2-148.5)				
Female	7	4.3	163.8	(65.6-337.5)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male 222 222.6 99.7 (87.1-113.8)				
Male	4	3.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	4	2.7	nc	(nc-nc)	Male 12 13.3 90.0 (46.5-157.2)				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female 5 7.8 64.1 (20.7-149.5)				
Male	29	28.7	101.1	(67.7-145.2)	<b><u>Testis</u></b>				
Female	11	16.2	68.1	(33.9-121.9)	Male 4 3.6 nc (nc-nc)				
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	7	8.8	79.9	(32.0-164.6)	Male 11 10.0 109.5 (54.6-196.0)				
Female	3	2.4	nc	(nc-nc)	Female 19 28.0 68.0 (40.9-106.1)				
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	19	20.2	94.1	(56.7-147.0)	Female 44 43.5 101.0 (73.4-135.6)				
Female	11	14.4	76.6	(38.2-137.0)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male 730 761.4 95.9 (89.0-103.1)				
Male	18	16.5	109.2	(64.7-172.6)	Female 676 673.4 100.4 (93.0-108.2)				
Female	3	5.6	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	86	109.4	78.6	(62.9-97.1)					
Female	100	104.5	95.7	(77.8-116.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Fitchburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	28	38.1	73.4	(48.8-106.1)	Male	16	25.3	63.3	(36.2-102.9)
Female	12	15.2	79.2	(40.9-138.3)	Female	13	21.8	59.6	(31.7-101.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	7.8	102.4	(44.1-201.8)	Male	12	6.6	182.7	(94.3-319.1)
Female	6	7.0	85.2	(31.1-185.5)	Female	7	5.7	122.2	(48.9-251.8)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	28	22.6	124.1	(82.5-179.4)
Female	113	149.8	75.4	(62.2-90.7)	Female	28	19.9	141.0	(93.7-203.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	8	5.8	138.6	(59.7-273.2)	Male	20	15.6	128.6	(78.5-198.6)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	24	44.5	53.9	(34.5-80.2)	Female	15	14.1	106.1	(59.4-175.1)
Female	35	50.3	69.6	(48.5-96.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	10	9.9	101.0	(48.3-185.7)	Male	15	12.2	122.5	(68.5-202.0)
Female	4	3.2	nc	(nc-nc)	Female	8	15.1	53.1	(22.9-104.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Stomach</u></b>				
Male	7	3.7	187.8	(75.2-387.0)	Male	8	8.9	90.3	(38.9-178.0)
Female	1	3.2	nc	(nc-nc)	Female	8	6.1	130.8	(56.3-257.7)
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Testis</u></b>				
Male	22	20.4	107.8	(67.6-163.3)	Male	5	6.1	82.2	(26.5-191.8)
Female	10	12.6	79.4	(38.0-145.9)	<b><u>Thyroid</u></b>				
<b><u>Larynx</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	5.8	nc	(nc-nc)	Female	46	33.7	136.5	(100.0-182.1)
Female	1	1.8	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	14	14.8	94.5	(51.6-158.6)	Male	472	513.4	91.9	(83.8-100.6)
Female	7	12.2	57.5	(23.1-118.6)	Female	489	538.5	90.8	(82.9-99.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>									
Male	8	11.5	69.3	(29.9-136.7)					
Female	4	4.3	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	82	69.3	118.3	(94.1-146.8)					
Female	97	76.2	127.2	(103.2-155.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Florida

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	1.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	1	2.9	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	1	1.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.6	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Male</u></b>				
Male	0	0.2	nc	(nc-nc)	10	15.5	64.7	(31.0-118.9)	
Female	0	0.0	nc	(nc-nc)	<b><u>Female</u></b>				
<b><u>Leukemia</u></b>					8				
Male	0	0.4	nc	(nc-nc)	9.9	80.8	(34.8-159.2)		
Female	0	0.2	nc	(nc-nc)					
<b><u>Liver and Intrahepatic Bile Ducts</u></b>									
Male	0	0.3	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	1	2.3	nc	(nc-nc)					
Female	2	1.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Foxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	17.3	98.5	(57.4-157.7)	Male	13	11.6	111.6	(59.4-190.9)
Female	5	6.0	83.0	(26.7-193.6)	Female	11	9.3	118.1	(58.9-211.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	3.5	143.7	(46.3-335.2)	Male	1	3.1	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	10	10.2	98.3	(47.1-180.9)
Female	69	68.5	100.7	(78.3-127.4)	Female	8	8.2	97.4	(41.9-191.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	2.6	nc	(nc-nc)	Male	5	7.4	68.0	(21.9-158.6)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	22	20.2	108.8	(68.2-164.7)	Female	12	6.2	194.5	(100.4-339.8)
Female	28	19.7	142.0	(94.3-205.3)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	7	5.7	123.6	(49.5-254.8)
Male	1	4.7	nc	(nc-nc)	Female	4	5.9	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	64	67.8	94.4	(72.7-120.5)
Male	0	1.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	1.2	nc	(nc-nc)	Male	5	4.0	124.5	(40.1-290.5)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	2	2.3	nc	(nc-nc)
Male	7	9.7	72.4	(29.0-149.3)	<b><u>Testis</u></b>				
Female	4	5.5	nc	(nc-nc)	Male	5	2.2	227.9	(73.4-531.8)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	2.7	nc	(nc-nc)	Male	5	4.0	123.7	(39.9-288.6)
Female	0	0.8	nc	(nc-nc)	Female	14	12.9	108.6	(59.3-182.2)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	6	6.5	92.2	(33.6-200.6)	Female	22	15.7	140.3	(87.9-212.4)
Female	6	4.8	124.5	(45.4-270.9)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	228	237.9	95.8	(83.8-109.1)
Male	4	5.5	nc	(nc-nc)	Female	249	231.3	107.6	(94.7-121.9)
Female	0	1.8	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	31	32.4	95.6	(64.9-135.6)					
Female	31	32.3	95.9	(65.2-136.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Framingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	52	68.9	75.5	(56.3-99.0)	Male	31	45.5	68.1	(46.3-96.7)
Female	27	25.8	104.7	(69.0-152.3)	Female	26	38.2	68.0	(44.4-99.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	13	13.4	96.8	(51.5-165.5)	Male	16	11.8	135.2	(77.2-219.6)
Female	6	11.9	50.3	(18.4-109.4)	Female	15	9.8	152.9	(85.5-252.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	2.1	nc	(nc-nc)	Male	37	40.2	92.1	(64.8-127.0)
Female	281	265.6	105.8	(93.8-118.9)	Female	27	34.1	79.1	(52.1-115.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	10	10.5	95.2	(45.6-175.1)	Male	19	28.3	67.2	(40.4-104.9)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	83	81.0	102.5	(81.6-127.0)	Female	21	24.8	84.8	(52.5-129.7)
Female	96	85.7	112.0	(90.7-136.7)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	23	22.2	103.4	(65.6-155.2)
Male	22	18.0	122.5	(76.7-185.5)	Female	23	25.6	90.0	(57.0-135.0)
Female	10	5.4	186.7	(89.4-343.3)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	250	255.2	98.0	(86.2-110.9)
Male	4	6.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	4	5.3	nc	(nc-nc)	Male	16	16.2	99.0	(56.5-160.8)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	17	10.4	163.8	(95.4-262.2)
Male	35	36.7	95.3	(66.4-132.6)	<b><u>Testis</u></b>				
Female	17	21.9	77.6	(45.2-124.3)	Male	8	10.4	77.1	(33.2-151.9)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	7	10.4	67.4	(27.0-138.9)	Male	19	15.7	121.1	(72.9-189.1)
Female	4	3.2	nc	(nc-nc)	Female	46	51.3	89.7	(65.6-119.6)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	27	26.1	103.6	(68.3-150.8)	Female	67	59.9	111.9	(86.7-142.1)
Female	29	20.5	141.1	(94.5-202.7)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	884	924.4	95.6	(89.4-102.1)
Male	16	20.7	77.3	(44.2-125.6)	Female	982	937.1	104.8	(98.3-111.6)
Female	7	7.4	95.0	(38.1-195.7)					
<b><u>Lung and Bronchus</u></b>									
Male	118	123.8	95.3	(78.9-114.2)					
Female	128	130.5	98.1	(81.8-116.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Franklin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	32	24.4	131.0	(89.6-184.9)	Male	17	17.7	96.0	(55.9-153.7)
Female	6	8.5	70.3	(25.7-153.1)	Female	17	15.0	113.1	(65.9-181.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	5.8	85.5	(27.6-199.5)	Male	6	4.4	135.4	(49.4-294.7)
Female	3	4.8	nc	(nc-nc)	Female	3	3.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	13	15.9	81.6	(43.4-139.5)
Female	108	107.3	100.6	(82.5-121.5)	Female	13	12.2	106.4	(56.6-182.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	4.6	nc	(nc-nc)	Male	14	11.8	119.0	(65.0-199.7)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	33	30.8	107.0	(73.6-150.2)	Female	7	9.5	73.8	(29.6-152.1)
Female	37	28.9	127.9	(90.0-176.3)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	8	8.1	98.6	(42.4-194.2)
Male	7	6.8	103.0	(41.3-212.2)	Female	11	8.4	131.4	(65.5-235.2)
Female	3	1.8	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	135	95.8	140.9	(118.1-166.8)
Male	0	2.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	5	2.2	232.1	(74.8-541.6)	Male	5	6.0	82.9	(26.7-193.4)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	4	3.4	nc	(nc-nc)
Male	16	14.8	107.8	(61.6-175.0)	<b><u>Testis</u></b>				
Female	10	8.3	120.5	(57.7-221.6)	Male	3	4.4	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	5	4.0	126.1	(40.6-294.2)	Male	7	6.9	101.9	(40.8-209.9)
Female	0	1.2	nc	(nc-nc)	Female	30	22.6	132.7	(89.5-189.4)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	11	10.3	107.1	(53.4-191.7)	Female	17	23.6	72.1	(42.0-115.4)
Female	7	7.6	92.4	(37.0-190.3)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	382	351.5	108.7	(98.0-120.1)
Male	7	8.3	83.9	(33.6-172.8)	Female	363	352.8	102.9	(92.6-114.1)
Female	2	2.6	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	31	44.7	69.4	(47.1-98.5)					
Female	40	45.6	87.7	(62.7-119.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;